<% (signals.list.current.rate).substr(0,9) %>
<% signal.analyst %>
<% signal.analyst %>
Last Updated: Mar 18, 2026 04:08:01 PM (GMT)
AZN: Current live price is 189.18, reflecting a percentage change of -0.1% from the previous price.
Support and Resistance Levels The current support levels are 191.45, 191.45, and 191.45, with a resistance level of 191.45 and a pivot point at 191.45.
Indicators RSI is at 38.19, showing a downtrend from 100 in the past, indicating bearish pressure. The ATR is at 0.13226 suggesting low volatility. The MACD indicates a bearish trend with MACD at -0.11225 and a signal line of -0.13355. The current Parabolic SAR is at 191.45, signaling a possible reversal or continuation.
Market Sentiment With the price below the pivot point of 191.45 and bearish indicators, a further decline in price is anticipated.
AZN Signals & Technical Analysis
Market Sentiment
Trend Indicators
Oscillators
Moving Averages
Pivot
About (AZN) AstraZeneca PLC CEDEAR
Company Background
AstraZeneca PLC CEDEAR (symbol: AZN) is a global biopharmaceutical company headquartered in Cambridge, United Kingdom. Established in 1999 through the merger of Astra AB and Zeneca Group PLC, AstraZeneca specializes in the discovery, development, and commercialization of prescription medicines. With a strong commitment to research and innovation, the company operates across various therapeutic areas including oncology, cardiovascular, renal, respiratory, and inflammation. AstraZeneca aims to deliver transformative medicines that improve patients’ lives worldwide.
Market Position
AstraZeneca has established itself as a leading player in the pharmaceutical industry, particularly noted for its robust pipeline and diverse portfolio of products. The company holds a significant market share, benefitting from strategic collaborations and partnerships that enhance its research capabilities and market reach. In Argentina, AstraZeneca continues to strengthen its position by providing high-quality healthcare solutions, ensuring accessibility to its innovative therapies for local patients. The firm’s commitment to sustainability and corporate responsibility further bolsters its reputation in the market, positioning it favorably among stakeholders and investors alike.
Key Financial Highlights
AstraZeneca has demonstrated solid financial performance in recent years, exhibiting strong sales growth driven by its successful product launches and expanding global presence. The company reported significant revenues, with a marked increase in its oncology segment, particularly from medications such as Lynparza and Tagrisso. AstraZeneca’s strategic focus on biologic therapies and personalized medicine has positioned it well for future growth. The company's dedication to research and development represents a substantial portion of its budget, underlining its commitment to innovation in the pharmaceutical sector. Furthermore, AstraZeneca's consistent dividend policy reflects its financial strength and commitment to returning value to shareholders.
Industry Highlights
As the pharmaceutical industry evolves, AstraZeneca is at the forefront of advancements in biotechnology and drug development. The company’s adaptive strategies in response to healthcare challenges, such as its rapid development of COVID-19 vaccines, underscore its agility and responsiveness to global health needs. With an ongoing emphasis on pipeline expansion and collaboration with leading research institutions, AstraZeneca is poised to leverage emerging trends and maintain its competitive edge in the global pharmaceutical landscape.
Sidebar rates
- <% signal.pair %>
<% signals.active.Current.rate.substr(0,7) %>
